Sarepta (SRPT) plans to continue Elevidys shipments for Duchenne muscular dystrophy, despite FDA request not to do so after patient deaths. Read more here.
Search Group
Share To
Comments
About Screade
Screade® Inc. version 125d372, copyright 2016 - 2025
Blocked Users
Customize Dark Theme
Forgot your password?
Forgot your password?
Invite your friends
Please type emails of people you want to invite, we will send them invitation email on your behalf. Separate emails with comma if you want to invite multiple friends.
Comments